| scholarly article | Q13442814 |
| P50 | author | David C. Montefiori | Q63302725 |
| P2093 | author name string | Pengfei Jiang | |
| Shan Lu | |||
| Shixia Wang | |||
| Emma T Crooks | |||
| James Binley | |||
| Michael Vaine | |||
| P2860 | cites work | Antibody vs. HIV in a clash of evolutionary titans | Q24536059 |
| Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies | Q24561905 | ||
| Structural definition of a conserved neutralization epitope on HIV-1 gp120 | Q24655948 | ||
| Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-52D | Q27643126 | ||
| Structure of Antibody F425-B4e8 in Complex with a V3 Peptide Reveals a New Binding Mode for HIV-1 Neutralization | Q27649247 | ||
| One step forward, two steps back--will there ever be an AIDS vaccine? | Q64376850 | ||
| Delivery of DNA to skin by particle bombardment | Q75224968 | ||
| Focusing the immune response on the V3 loop, a neutralizing epitope of the HIV-1 gp120 envelope | Q80150785 | ||
| GP120: target for neutralizing HIV-1 antibodies | Q28303124 | ||
| Antibody neutralization and escape by HIV-1 | Q29547345 | ||
| Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies | Q29614531 | ||
| Rapid evolution of the neutralizing antibody response to HIV type 1 infection | Q29618603 | ||
| Structure of a V3-containing HIV-1 gp120 core | Q29619014 | ||
| Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies | Q29619015 | ||
| Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. | Q31016954 | ||
| Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. | Q33647300 | ||
| Mapping of epitopes exposed on intact human immunodeficiency virus type 1 (HIV-1) virions: a new strategy for studying the immunologic relatedness of HIV-1. | Q33785510 | ||
| Cross-subtype neutralizing antibodies induced in baboons by a subtype E gp120 immunogen based on an R5 primary human immunodeficiency virus type 1 envelope | Q33813526 | ||
| Enhanced immunogenicity of gp120 protein when combined with recombinant DNA priming to generate antibodies that neutralize the JR-FL primary isolate of human immunodeficiency virus type 1. | Q33843103 | ||
| Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1 | Q33883887 | ||
| Comparing antigenicity and immunogenicity of engineered gp120. | Q33984309 | ||
| Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants | Q34302085 | ||
| A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1 | Q34306804 | ||
| The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection | Q34317025 | ||
| Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. | Q34434854 | ||
| Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterolo | Q35024202 | ||
| Identifying epitopes of HIV-1 that induce protective antibodies | Q35708836 | ||
| Antigenic and immunogenic study of membrane-proximal external region-grafted gp120 antigens by a DNA prime-protein boost immunization strategy | Q35785338 | ||
| Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors | Q35857221 | ||
| Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection | Q35857268 | ||
| The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolate | Q35869892 | ||
| Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160. | Q35886254 | ||
| Isolation and characterization of monoclonal antibodies elicited by trimeric HIV-1 Env gp140 protein immunogens | Q36103090 | ||
| A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120. | Q36149102 | ||
| Antigenic conservation and immunogenicity of the HIV coreceptor binding site | Q36403587 | ||
| Structural studies of human HIV-1 V3 antibodies. | Q36487158 | ||
| Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers | Q36528901 | ||
| Broad HIV-1 neutralization mediated by CD4-binding site antibodies | Q36977635 | ||
| Characterizing anti-HIV monoclonal antibodies and immune sera by defining the mechanism of neutralization. | Q37072702 | ||
| Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies | Q39698363 | ||
| Identification of two neutralizing regions on the severe acute respiratory syndrome coronavirus spike glycoprotein produced from the mammalian expression system. | Q40471278 | ||
| A DNA vaccine producing LcrV antigen in oligomers is effective in protecting mice from lethal mucosal challenge of plague | Q41461629 | ||
| Crystal structures of human immunodeficiency virus type 1 (HIV-1) neutralizing antibody 2219 in complex with three different V3 peptides reveal a new binding mode for HIV-1 cross-reactivity | Q42031529 | ||
| Postnatal pre- and postexposure passive immunization strategies: protection of neonatal macaques against oral simian-human immunodeficiency virus challenge | Q44159819 | ||
| Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E. | Q45417687 | ||
| Definitive toxicology and biodistribution study of a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 (HIV-1) vaccine in rabbits | Q45423354 | ||
| Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors | Q45772545 | ||
| Prevention of HIV-1 infection in chimpanzees by gpl20 V3 domain-specific monoclonal antibody | Q46352552 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 15 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| P304 | page(s) | 7369-7378 | |
| P577 | publication date | 2008-05-21 | |
| P1433 | published in | Journal of Virology | Q1251128 |
| P1476 | title | Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccination | |
| P478 | volume | 82 |
| Q40294097 | A cGAS-Independent STING/IRF7 Pathway Mediates the Immunogenicity of DNA Vaccines. |
| Q38206520 | A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs |
| Q41819464 | A novel rabbit monoclonal antibody platform to dissect the diverse repertoire of antibody epitopes for HIV-1 Env immunogen design |
| Q34444535 | A versatile vector for the production of pseudotyped viruses expressing gp120 antigens from different clades of primary HIV-1 isolates. |
| Q91967266 | AIDS Vaccine Research Subcommittee (AVRS) Consultation: Early-Life Immunization Strategies against HIV Acquisition |
| Q33759392 | Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity. |
| Q35580892 | Antigenicity and immunogenicity of a trimeric envelope protein from an Indian clade C HIV-1 isolate |
| Q35774051 | Biochemically defined HIV-1 envelope glycoprotein variant immunogens display differential binding and neutralizing specificities to the CD4-binding site |
| Q33955745 | Boosting of HIV-1 neutralizing antibody responses by a distally related retroviral envelope protein |
| Q33725679 | Breadth of neutralizing antibodies elicited by stable, homogeneous clade A and clade C HIV-1 gp140 envelope trimers in guinea pigs |
| Q30418340 | Broader neutralizing antibodies against H5N1 viruses using prime-boost immunization of hyperglycosylated hemagglutinin DNA and virus-like particles |
| Q90370118 | Cell surface ectodomain integrity of a subset of functional HIV-1 envelopes is dependent on a conserved hydrophilic domain containing region in their C-terminal tail |
| Q92640002 | Characterization of protective humoral and cellular immune responses against RHDV2 induced by a new vaccine based on recombinant baculovirus |
| Q28732043 | Co-immunization with multimeric scaffolds and DNA rapidly induces potent autologous HIV-1 neutralizing antibodies and CD8+ T cells |
| Q85019741 | Comparative reactivity of serum samples from Argentinean HIV-infected patients with V3 peptides from subtype B or BF recombinants |
| Q37530450 | Cross reactivity of serum antibody responses elicited by DNA vaccines expressing HA antigens from H1N1 subtype influenza vaccines in the past 30 years. |
| Q37329415 | Cross-clade neutralizing antibodies against HIV-1 induced in rabbits by focusing the immune response on a neutralizing epitope. |
| Q38581981 | DNA Immunization for HIV Vaccine Development |
| Q40715606 | DNA Vaccines Against Maedi-Visna Virus. |
| Q37576264 | DNA immunization |
| Q36694841 | DNA prime-protein boost using subtype consensus Env was effective in eliciting neutralizing antibody responses against subtype BC HIV-1 viruses circulating in China. |
| Q35640984 | DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers |
| Q42084754 | Dynamic features of the selective pressure on the human immunodeficiency virus type 1 (HIV-1) gp120 CD4-binding site in a group of long term non progressor (LTNP) subjects. |
| Q47431246 | Eliciting broad neutralizing antibody to HIV-1: envelopes of different lentivirus cross immunization by prime-boost vaccination |
| Q34016706 | Eliciting neutralizing antibodies with gp120 outer domain constructs based on M-group consensus sequence |
| Q33769283 | Env-expressing autologous T lymphocytes induce neutralizing antibody and afford marked protection against feline immunodeficiency virus |
| Q39402539 | HIV-1 virus-like particles bearing pure env trimers expose neutralizing epitopes but occlude nonneutralizing epitopes |
| Q37509586 | Heterologous prime-boost vaccination. |
| Q40568483 | Holes in the Glycan Shield of the Native HIV Envelope Are a Target of Trimer-Elicited Neutralizing Antibodies |
| Q30432382 | Human immunodeficiency virus vaccine an update |
| Q40130744 | Identification and characterization of a naturally occurring, efficiently cleaved, membrane-bound, clade A HIV-1 Env, suitable for immunogen design, with properties comparable to membrane-bound BG505. |
| Q36827300 | Identification of an HIV-1 clade A envelope that exhibits broad antigenicity and neutralization sensitivity and elicits antibodies targeting three distinct epitopes |
| Q38009870 | Improved outlook on HIV-1 prevention and vaccine development |
| Q37588371 | Improvement of antibody responses by HIV envelope DNA and protein co-immunization. |
| Q35893538 | Improving immunogenicity of HIV-1 envelope gp120 by glycan removal and immune complex formation |
| Q37252966 | Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization |
| Q45129797 | Intramuscular delivery of a cholera DNA vaccine primes both systemic and mucosal protective antibody responses against cholera |
| Q40824275 | Membrane bound Indian clade C HIV-1 envelope antigen induces antibodies to diverse and conserved epitopes upon DNA prime/protein boost in rabbits. |
| Q40442031 | Membrane bound modified form of clade B Env, JRCSF is suitable for immunogen design as it is efficiently cleaved and displays all the broadly neutralizing epitopes including V2 and C2 domain-dependent conformational epitopes. |
| Q33837530 | Mucosal vaccines against respiratory syncytial virus |
| Q33683203 | Multi-Parameter Exploration of HIV-1 Virus-Like Particles as Neutralizing Antibody Immunogens in Guinea Pigs, Rabbits and Macaques |
| Q35826610 | Pilot Study on the Use of DNA Priming Immunization to Enhance Y. pestis LcrV-Specific B Cell Responses Elicited by a Recombinant LcrV Protein Vaccine. |
| Q36694846 | Pilot study on the immunogenicity of paired Env immunogens from mother-to-child transmitted HIV-1 isolates |
| Q41899304 | Potent monoclonal antibodies against Clostridium difficile toxin A elicited by DNA immunization |
| Q34551010 | Prime-boost immunization of rabbits with HIV-1 gp120 elicits potent neutralization activity against a primary viral isolate |
| Q36974754 | Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. |
| Q30379200 | Progress on the induction of neutralizing antibodies against HIV type 1 (HIV-1). |
| Q82763047 | Protein prime-peptide boost as a new strategy induced an Eppin dominant B-cell epitope specific immune response and suppressed fertility |
| Q37336704 | Robust neutralizing antibodies elicited by HIV-1 JRFL envelope glycoprotein trimers in nonhuman primates |
| Q27487961 | Sang Froid in a time of trouble: is a vaccine against HIV possible? |
| Q41933070 | Screening of primary gp120 immunogens to formulate the next generation polyvalent DNA prime-protein boost HIV-1 vaccines |
| Q34982715 | Sequential immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in vivo development of neutralizing antibodies |
| Q34456367 | Serum neutralizing activities from a Beijing homosexual male cohort infected with different subtypes of HIV-1 in China |
| Q38712684 | Stabilization of a soluble, native-like trimeric form of an efficiently cleaved Indian HIV-1 clade C envelope glycoprotein |
| Q28534454 | Stabilizing exposure of conserved epitopes by structure guided insertion of disulfide bond in HIV-1 envelope glycoprotein |
| Q35909563 | Structural analysis of a novel rabbit monoclonal antibody R53 targeting an epitope in HIV-1 gp120 C4 region critical for receptor and co-receptor binding. |
| Q40438707 | Structure-based Design of Cyclically Permuted HIV-1 gp120 Trimers That Elicit Neutralizing Antibodies |
| Q55250836 | The wide utility of rabbits as models of human diseases. |
| Q35076664 | Two closely related Env antigens from the same patient elicited different spectra of neutralizing antibodies against heterologous HIV-1 isolates |
| Q27319450 | Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site |
Search more.